Jon Northrup, former CEO and Co-Founder of Beta Cat Pharmaceuticals, presented at our Western Regional Patient Meeting in Salt Lake City in April on the company’s upcoming, first-in-human trial of Tegavivint (BC2059) in desmoid tumors. You can learn more about this trial at clinicaltrials.gov/ct2/show/NCT03459469?term=desmoid+tumor
